Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide: A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 6, 2003, Pages 414-419

  Schürer, Michael ^a   Erb, Katharina ^b   Junge, Klaus ^c   Schäfer, Harald F ^d   Schulz, Hans Ulrich ^a   Amschler, Stefan ^a   Krupp, Sabine ^a   Hermann, Robert ^c  

^a LAFAA Lab Contract Res Clin P   (Germany)

^b Appl Clinical Pharmacology Services   (Germany)

^c ASTA MEDICA AG   (Germany)

^d Arzneimittelwerk Dresden GmbH   (Germany)

Author keywords

CAS 58 93 5; CAS 83602 05 5; CAS 94841 17 5; Hydrochlorothiazide, bioequivalence, combination with spirapril, drug drug interaction; Quadroplus ; Quadropril

Indexed keywords

HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS SPIRAPRIL; QUADROPLUS; SPIRAPRIL; SPIRAPRILAT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TABLET;

EID: 0038434534     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297129     Document Type: Article

References (10)

1. Spirapril monography. R. K. Klasco, C. R. Gelman (eds.), Drugdex® System. Micromedex, Greenwood Village, Colorado, Edition 100, 1974-1999
2. Hydrochlorothiazide monography. R. K. Klasco, C. R. Gelman (eds.), Drugdex® System. Micromedex, Greenwood Village, Colorado, Edition 100, 1974-1999
3. Schürer, M., Amschler, S., Schulz, H.-U. et al., Simultaneous determination of spirapril and spiraprilat in plasma by capillary gas chromatography-mass spectrometry. Arzneim.Forsch./Drug Res. 53, 307 (2003)
4. Van der Meer, M. J., Brown L. W., Simultaneous determination of amiloride and hydrochlorothiazide in plasma by reversed-phase high-performance liquid chromatography. J. Chromatog. 423, 351 (1987)
5. Steinijans, V. W., Hartmann, M., Huber, R. et al., Lack of pharmacokinetic interaction as an equivalence problem. Int. J. Clin. Pharmacol. Ther. Toxicol. 29, 323 (1991)
6. Steinijans, V. W., Hauschke, D., International harmonization of regulatory bioequivalence requirements. Clin. Res. Regulat. Affairs 10, 203 (1993)
7. CPMP Working Party on Efficacy of Medicinal Products, Note for Guidance: Investigation of Bioavailability and Bioequivalence (1991)
8. Guidance: Statistical procedures for bioequivalence studies using a standard two-treatment crossover design, FDA, Division of bioequivalence, Rockville, MD (1992)
9. Diletti, E., Hauschke, D., Steinijans, V. W., Sample size determination for bioequivalence assessment by means of confidence intervals. Int. J. Clin. Pharmacol. Ther. Toxicol. 29, 1 (1991)
10. Diletti, E., Hauschke, D., Steinijans, V. W., Sample size determination: Extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Int. J. Clin. Pharmacol. Ther. Toxicol. 30 (Suppl. 1), 59 (1992)